131 related articles for article (PubMed ID: 8554933)
1. Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis.
Demnati R; Michoud MC; Jeanneret-Grosjean A; Ong H; Du Souich P
Br J Clin Pharmacol; 1995 Oct; 40(4):319-24. PubMed ID: 8554933
[TBL] [Abstract][Full Text] [Related]
2. Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.
Bethke TD; Giessmann T; Westphal K; Weinbrenner A; Hauns B; Hauschke D; David M; Lahu G; Zech K; Hermann R; Siegmund W
Int J Clin Pharmacol Ther; 2006 Nov; 44(11):572-9. PubMed ID: 17176624
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers.
Lipworth BJ; Clark DJ; Koch P; Arbeeny C
Thorax; 1997 Oct; 52(10):849-52. PubMed ID: 9404370
[TBL] [Abstract][Full Text] [Related]
4. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics.
Lima JJ; Thomason DB; Mohamed MH; Eberle LV; Self TH; Johnson JA
Clin Pharmacol Ther; 1999 May; 65(5):519-25. PubMed ID: 10340917
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and systemic beta2-adrenoceptor-mediated responses to inhaled salbutamol.
Fowler SJ; Lipworth BJ
Br J Clin Pharmacol; 2001 Apr; 51(4):359-62. PubMed ID: 11318774
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers.
Du XL; Zhu Z; Fu Q; Li DK; Xu WB
Acta Pharmacol Sin; 2002 Jul; 23(7):663-6. PubMed ID: 12100764
[TBL] [Abstract][Full Text] [Related]
7. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma.
Smyth ET; Pavord ID; Wong CS; Wisniewski AF; Williams J; Tattersfield AE
BMJ; 1993 Feb; 306(6877):543-5. PubMed ID: 8096416
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects.
Gumbhir-Shah K; Kellerman DJ; DeGraw S; Koch P; Jusko WJ
Pulm Pharmacol Ther; 1999; 12(6):353-62. PubMed ID: 10587476
[TBL] [Abstract][Full Text] [Related]
9. Effects of airway calibre on lung delivery of nebulised salbutamol.
Lipworth BJ; Clark DJ
Thorax; 1997 Dec; 52(12):1036-9. PubMed ID: 9516895
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms.
Boger E; Fridén M
J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):1-12. PubMed ID: 29878860
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of levosalbutamol: what are the clinical implications?
Boulton DW; Fawcett JP
Clin Pharmacokinet; 2001 Jan; 40(1):23-40. PubMed ID: 11236808
[TBL] [Abstract][Full Text] [Related]
12. Blood and urinary concentrations of salbutamol in asthmatic subjects.
Elers J; Pedersen L; Henninge J; Lund TK; Hemmersbach P; Dalhoff K; Backer V
Med Sci Sports Exerc; 2010 Feb; 42(2):244-9. PubMed ID: 19927035
[TBL] [Abstract][Full Text] [Related]
13. Equivalence of pharmacokinetic characteristics and bronchodilating effect between two combined formulations of nedocromil sodium and salbutamol: MDI and nebulizer solution.
Reggio S; Bustacchini S; Pistelli R; Valente S
Int J Clin Pharmacol Res; 1996; 16(1):19-27. PubMed ID: 9001926
[TBL] [Abstract][Full Text] [Related]
14. Enantioselective disposition of salbutamol in man following oral and intravenous administration.
Boulton DW; Fawcett JP
Br J Clin Pharmacol; 1996 Jan; 41(1):35-40. PubMed ID: 8824691
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of (R,S)-Albuterol after aerosol inhalation in healthy adult volunteers.
Anderson PJ; Zhou X; Breen P; Gann L; Logsdon TW; Compadre CM; Hiller FC
J Pharm Sci; 1998 Jul; 87(7):841-4. PubMed ID: 9649352
[TBL] [Abstract][Full Text] [Related]
16. [Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers].
Du XL; Zhu Z; Fu Q; Li DK; Xu WB
Yao Xue Xue Bao; 2001 Aug; 36(8):616-20. PubMed ID: 12579942
[TBL] [Abstract][Full Text] [Related]
17. Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device.
Clark DJ; Lipworth BJ
Thorax; 1996 Oct; 51(10):981-4. PubMed ID: 8977596
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers.
Gumbhir-Shah K; Kellerman DJ; DeGraw S; Koch P; Jusko WJ
J Clin Pharmacol; 1998 Dec; 38(12):1096-106. PubMed ID: 11301561
[TBL] [Abstract][Full Text] [Related]
19. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.
Bennett JA; Tattersfield AE
Thorax; 1997 May; 52(5):458-64. PubMed ID: 9176539
[TBL] [Abstract][Full Text] [Related]
20. Metered dose inhaler salbutamol treatment of asthma in the ED: comparison of two doses with plasma levels.
Rodrigo G; Rodrigo C
Am J Emerg Med; 1996 Mar; 14(2):144-50. PubMed ID: 8924135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
